Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
Key claim: A multi-center, randomized, double-blind, placebo-controlled Phase 1/2 trial is evaluating the efficacy and safety of investigational agent EN001 in patients with sarcopenia.
Abstract
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Sarcopenia
Why this matters
Sarcopenia remains a core healthspan target with no approved pharmacological therapy, so any investigational agent entering controlled human testing expands the small pool of drug candidates alongside myostatin/activin inhibitors, SARMs, and mitochondria-targeted muscle therapeutics. A Phase 1/2 RCT establishes EN001 on the human-evidence ladder but produces no efficacy readout yet — it is a trial-in-progress signal, not an outcome.